Variant · Expression
MKI67 EXPRESSION
CI-VAR-00000945Explore in graph →CIViC 624
Curated evidence
Evidence by cancer (2 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26341751
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Breast Neoplasm1 | ||||||||
| MKI67 EXPRESSION | (prognostic) | Prognostic | B | Supports Poor Outcome | 4 | accepted | EID1593A quantitative meta-analysis was performed to assess optimal IHC-calculated cutoff values for the prognostic use of proliferative biomarker Ki67 in breast cancer. The studies included ER positive and … (full text at CIViC) PMID 26341751 · Petrelli et al., 2015 · Open in CIViC | civic |
| Malignant Prostate Neoplasm1 | ||||||||
| MKI67 EXPRESSION | (prognostic) | Prognostic | B | Supports Poor Outcome | 3 | accepted | EID1594293 cases of clinically localized prostate cancer were analyzed on needle-biopsy FFPE tissue microarray, using the MIB-1 antibody against the Ki67 marker of proliferation. IHC staining was used to gen… (full text at CIViC) PMID 23329234 · | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available